Advertisement

Related Videos

David A. Hyman, MD, JD, on Inclusive Shared Savings

Ian Tannock, MD, PhD, DSc, on Near-Equivalence: A Better Question Than Non-Inferiority

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

Focus on Optimized Dosing of Ibrutinib Panel Discussion

Boon-Cher Goh, MD, on Cancer Drugs in Singapore: 3As (Availability, Accessibility, and Affordability)

Advertisement

Advertisement




Nov
09
Today In Oncology
Impact of Concomitant Noncancer Medications on Outcomes in Breast Cancer
NCCN Guidelines to Be Integrated Into OpenEvidence Medical AI Platform
Adding an Investigational Monoclonal Antibody to Ibrutinib May Allow Patients With CLL to Discontinue Daily Treatment
FDA Approves Daratumumab and Hyaluronidase-fihj for High-Risk Smoldering Multiple Myeloma
Armando Giuliano Honored With 2025 William L. McGuire Memorial Lecture Award
View More 
Advertisement
© 2025 HSP News Service, L.L.C.
Conexiant Oncology Logo